Experts share insights into how LDL & HDL levels are affected by inflammation & the treatment of rheumatic disease, addressing how targeting these levels may improve cardiovascular outcomes for patients.
Search results for: Tofacitinib
Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…
Update on Extrapulmonary Sarcoidosis
Neurosarcoidosis & sarcoid dermatopathology are discussed.
Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed
Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.
From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management
During the ACR Convergence 2021 Review Course, Rohit Aggarwal, MD, MS, provided an update on idiopathic inflammatory myopathy.
FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting
ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence…
Clinical Rheumatology Year in Review 2021
ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…
Opening Session of ACR Convergence 2021 Takes on Burnout, Pandemic Challenges & Moving Toward a New Normal
Keynote speaker Seema Yasmin, MD, brought her unique perspective to moving past the pandemic to improve provider mental health, address vaccine hesitancy and prepare for future health crises.
Psoriatic Arthritis Treatment Update
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…
Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis
Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 20
- Next Page »